INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTS

In the retrospective multicenter study during 2007–2017 we included 59 oncohematological patients with mucormycosis and 541 patients with invasive aspergillosis. Our study showed that mucomorhycosis more often developed in children and adolescents (p = 0.001), and after «graft versus host» disease development (p = 0.0001). Patients with mucormycosis were more immunosuppressed: severe neutropenia was in 88 % vs. 82 %, median duration of neutropenia ‒ 30 days vs. 14 days, p = 0.0001, lymphocytopenia – 77 % vs. 65 %, median duration of lymphocytopenia – 25 days vs. 14 days, p = 0.001. The main sites of infection were lungs, nevertheless in patients with mucormycosis it was less frequent (73 % vs. 97 %, p = 0.02), but more frequent were ≥2 organs involvement (42 % vs. 8 %, p = 0.001) and paranasal sinuses involvement (15 % vs. 6 %, p = 0.04). Typical clinical features of mucomorhycosis were localized pain syndrome (53 % vs. 5 %, p = 0.0001), hemoptysis (32 % vs. 6 %, p = 0.001), on lung computed tomography scan – pleural effusion (53 % vs. 7 %, p = 0.003), lesions with destruction (38 % vs. 8 %, p = 0.0001) and “a reverse halo” symptom (17 % vs. 3 %). The overall 12-week survival was significantly lower in patients with mucormycosis (49 % vs. 81 %, p = 0.0001). In both groups unfavorable prognosis factors were: ≥2 organs involvement (p = 0.0009) and concomitant bacterial or viral infection (p = 0.001 and p = 0.008 respectively). In mucormycosis patients favorable prognosis factor was remission of underlying disease (p = 0.006), in invasive aspergillosis patients – early bronchoscopy (p = 0.003), voriconazole use (p = 0.0007) and secondary antifungal prophylaxis (p = 0.0001).

1.

2. Skiada A., Lass-Floerl C., Klimko N. et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018;56(Suppl 1):93–101. DOI: 10.1093/mmy/myx101. PMID: 29538730.

3. Tissot F., Agrawal S., Pagano L. et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017;102(3):433–44. DOI: 10.3324/haematol.2016.152900. PMID: 28011902.

4. Ullmann A.J., Aguado J.M., ArikanAkdagli S. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24(Suppl 1):e1–38. DOI: 10.1016/j.cmi.2018.01.002. PMID: 29544767.

5. De Pauw B., Walsh T.J., Donnelly J.P. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases 2008;46(12):1813–21. DOI: 10.1086/588660. PMID: 18462102.

6. Lewis R.E., Cahyame-Zuniga L., Leventakos K. et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 2013;56(6):638–45. DOI: 10.1111/myc. 12081. PMID: 23551865.

7. Mariette C., Tavernier E., Hocquet D. et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leuk Lymphoma 2017;58(3):586–93. DOI: 10.1080/10428194.2016.1204652. PMID: 27397551.

8. Kontoyiannis D.P., Marr K.A., Park B.J. et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;50(8):1091–100. DOI: 10.1086/651263. PMID: 20218877.

9. Kurosawa M., Yonezumi M., Hashino S. et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2012;96(6):748–57. DOI: 10.1007/s12185-012-1210-y. PMID: 23111539.

10. Kontoyiannis D., Hongbo Y., Jinlin S. et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis 2016;16(1):730. DOI: 10.1186/s12879-016-2023-z. PMID: 27905900.

11. Lanternier F., Dannaoui E., Morizot G. et al. A global analysis of mucormycosis in France: The RetroZygo Study (2005– 2007). Clin Infect Dis 2012;54(Suppl 1): S35–43. DOI: 10.1093/cid/cir880. PMID: 22247443.

12. Lestrade P., van der Velden W., Bouwman F. et al. Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a singlecentre retrospective cohort study. J Antimicrob Chemother 2018;73(5):1389–94. DOI: 10.1093/jac/dkx527. PMID: 29394399.

13. Babor F., Schuster F., Mackenzie C. et al. Invasive aspergillosis in pediatric oncology patients: a rare event with poor prognosiscase analysis to plan better targeted prophylactic or therapeutic measurement. Klin Padiatr 2012;224(3):160–5. DOI: 10.1055/s-0032-1304625. PMID: 22504775.

14. Guinea J., Escribano P., Vena A. et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates.PLoS ONE 2017;12(6):e0179136. DOI: 10.1371/journal.pone. 0179136. PMID: 28591186.

15. Hammond S.P., Baden L.R., Marty F.M. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother 2011;55(11):5018–21. DOI: 10.1128/AAC.00536–11. PMID: 21876046.

16. Lafaurie M., Lapalu J., Raffoux E. et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 2010;16(8):1191–6. DOI: 10.1111/j.1469-0691.2009.03050.x. PMID: 19735276.

17. Steinbach W.J., Marr K.A., Anaissie E.J. et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH alliance registry. J Infect 2012;65(5):453–64. DOI: 10.1016/j.jinf.2012.08.003. PMID: 22898389.

18. Klimko N.N., Khostelidi S.N., Popova M.O. et al. Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia. Mycoses 2014;57 (Suppl 3):91–6. DOI: 10.1111/myc.12247. PMID: 25187314.

19. Saegeman V., Maertens J., Ectors N. et al. Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital. Medical Mycology 2010;48(2):245–54. DOI: 10.3109/13693780903059477. PMID: 19568978.

20. Klimko N., Khostelidi S., Shadrivova O. et al.Mucormycosis in oncohematology patients (results of the prospective study).Onkogematologiya = Oncohematology 2017;12(2):14–22. (In Russ.). DOI: 10.17650/1818-8346-2017-12-2-14-22.

21. Nicolle M.C., Bénet T., Thiebaut A. et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004to 2009. Haematologica 2011;96(11):1685–91. DOI: 10.3324/haematol. 2011.044636. PMID: 21791468.

22. Jung J., Kim Y., Lee H.J. et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect 2015;21(7):684. DOI: 10.1016/j. cmi. 2015.03.019. PMID: 25882362.

23. Legouge C., Caillot D., Chrétien M.L. et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis 2014;58(5):672–8. DOI: 10.1093/cid/cit929. PMID: 24352351.

24. Georgiadou S.P., Sipsas N.V., Marom E.M., Kontoyiannis D.P.The diagnostic value of halo and reversed halo signs for invasive mold infectionsin compromised hosts. Clin Infect Dis 2011;52(9): 1144–55. DOI: 10.1093/cid/cir122. PMID: 21467021.

25. Pagano L., Caira M., Candoni A. et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010;95(4):644–50. DOI: 10.3324/haematol.2009.012054. PMID: 19850903.

26. Cho S.Y., Lee D.G., Choi J.K. et al. Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species. Medicine (Baltimore) 2017;96(49):e8841. DOI: 10.1097/MD.0000000000008841. PMID: 29245249.

27. Herbrecht R., Patterson T.F., Slavin M.A. et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin b for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization forResearch and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 2015;60(5):713–20. DOI: 10.1093/cid/ciu911. PMID: 25414266.

28. Maertens J.A., Raad I.I., Marr K.A. et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016;387(10020):760–9. DOI: 10.1016/S0140-6736(15)01159-9. PMID: 26684607.

29. Zeidner J.F., Karp J.E., Blackford A.L. et al. Phase I clinical trials in acute myeloid leukemia: 23-year experience from Cancer Therapy Evaluation Program of the National Cancer Institute. J Natl Cancer Inst 2016;108(3). DOI: 10.1093/jnci/djv335. PMID: 26553781.